Biogen Inc
NASDAQ:BIIB
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
155.43
267.71
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Biogen Inc
Biogen Inc
Revenue
Biogen Inc
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Biogen Inc
NASDAQ:BIIB
|
Revenue
$9.6B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
1%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Revenue
$55.5B
|
CAGR 3-Years
0%
|
CAGR 5-Years
11%
|
CAGR 10-Years
11%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Revenue
$28.3B
|
CAGR 3-Years
1%
|
CAGR 5-Years
5%
|
CAGR 10-Years
3%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Revenue
$32.5B
|
CAGR 3-Years
8%
|
CAGR 5-Years
7%
|
CAGR 10-Years
5%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Revenue
$10.6B
|
CAGR 3-Years
14%
|
CAGR 5-Years
24%
|
CAGR 10-Years
30%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Revenue
$13.8B
|
CAGR 3-Years
1%
|
CAGR 5-Years
16%
|
CAGR 10-Years
18%
|
|
Biogen Inc
Revenue Breakdown
Breakdown by Geography
Biogen Inc
Breakdown by Segments
Biogen Inc
|
Total Revenue:
9.8B
USD
|
|
Product Revenue, Net:
7.2B
USD
|
|
Subtotal: Multiple Sclerosis:
4.7B
USD
|
|
Tysabri:
1.9B
USD
|
|
Subtotal: Rare Disease:
1.8B
USD
|
|
Spinraza:
1.7B
USD
|
|
Revenue From Anti-Cd20 Therapeutic Programs:
1.7B
USD
|
|
Total Fumarate:
1.6B
USD
|
|
Royalty Revenue On Sales Of Ocrevus:
1.3B
USD
|
|
Total Interferon:
1.1B
USD
|
|
Tecfidera:
1B
USD
|
|
Contract Manufacturing, Royalty And Other Rev...:
899.3m
USD
|
|
Contract Manufacturing Revenue:
848.2m
USD
|
|
Avonex:
811m
USD
|
|
Subtotal: Biosimilars:
770m
USD
|
|
Vumerity:
576.3m
USD
|
|
Benepali:
438.8m
USD
|
|
Plegridy:
294.7m
USD
|
|
Imraldi:
222.1m
USD
|
|
Fampyra:
90.5m
USD
|
|
Flixabi:
77.4m
USD
|
|
Completed Technology For Skyclarys (United St...:
55.9m
USD
|
|
Royalty And Other Revenue:
51.1m
USD
|
|
Byooviz:
31.7m
USD
|
|
Other:
11.8m
USD
|
|
Qalsody:
5.9m
USD
|
Biogen Inc
Glance View
Biogen Inc. is a renowned biotechnology company that has carved out a niche in the development and delivery of groundbreaking therapies for neurological diseases. Founded in 1978, the company has focused on addressing some of the most challenging and complex health conditions, particularly multiple sclerosis (MS) and Alzheimer’s disease. With a robust pipeline of innovative treatments, Biogen aims to improve the lives of individuals affected by debilitating neurological disorders. Its flagship products, including drugs such as Tecfidera and Avonex, have notably solidified Biogen's reputation as a leader in MS treatment, contributing significantly to its revenue stream and positioning the company as a pivotal player in the biopharmaceutical landscape. In recent years, Biogen has expanded its focus to tackle Alzheimer’s disease, with the controversial introduction of Aduhelm, the first new Alzheimer’s treatment in nearly two decades. This move has drawn both attention and scrutiny from investors and healthcare professionals alike, highlighting the intense debates around pricing, efficacy, and regulatory oversight in the biotech sector. As Biogen continues to innovate, it is also making strides in strategic partnerships and collaborations to enhance its research capabilities and broaden its therapeutic offerings. With a strong commitment to enhancing patient outcomes and a growing reputation for scientific excellence, Biogen presents a compelling investment opportunity, albeit with the inherent risks associated with the dynamic and rapidly evolving field of biotechnology.
See Also
What is Biogen Inc's Revenue?
Revenue
9.6B
USD
Based on the financial report for Sep 30, 2024, Biogen Inc's Revenue amounts to 9.6B USD.
What is Biogen Inc's Revenue growth rate?
Revenue CAGR 10Y
1%
Over the last year, the Revenue growth was -4%. The average annual Revenue growth rates for Biogen Inc have been -5% over the past three years , -8% over the past five years , and 1% over the past ten years .
You don't have any saved screeners yet
